


TRANSITION FROM PHENOBARBITAL TO PEXION®

Prepared by the Canine Epilepsy Advisory Group: Sigitas Cizinauskas, Robyn Farquhar, Gualtiero Gandini, Jacques Penderis, Kai Rentmeister, Jean Laurent Thibaud, Sandra Tyler, Holger Volk

Transition from phenobarbital to Pexion®



*See Pexion® Dose Adjustment Protocol.

†If seizure control deteriorates on Pexion® monotherapy, consider additional medication.

‡Rate of dose adjustment may change according to clinical status of patient.

§Consider the potential of withdrawal seizures.



Australia: Boehringer Ingelheim Pty Limited. ABN 52 000 452 308. Animal Health Division, 78 Waterloo Road, North Ryde NSW 2113. Toll Free 1800 038 037. Fax Number 02 8875 8715.
 New Zealand: Boehringer Ingelheim (NZ) Ltd. Animal Health Division, Level 1, Unit 9, 42 Ormiston Road, East Tamaki, Auckland. Toll Free 0800 802 461. Fax Number 09 271 0629.
 Restricted Veterinary Medicine. Access is only through a Veterinary Authorisation. Pexion® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, 55216 Ingelheim/Rhein.
 For further information relating to transition, dose adjustment and treatment protocols, please contact our Technical Services Veterinarian on the toll free number.

Introducing
Pexion®

For *all* the reasons.